Please login to the form below
Letermovir
This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.
EC grants MSD’s Prevymis orphan product designation
The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate patients
Latest news
-
CHMP backs MSD’s CMV infection treatment
Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved
-
Merck says drug for CMV in transplant patients hits targets
Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Pharma deals during October 2012
CMV) and related assets. Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Communique - Communiqué Awards
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
